Albert Schömig’s area of research is vascular and stem cell biology with a special focus on diseases of the coronary vessels, antithrombotic strategies and inducible pluripotent stem cells. One of his academic concentrations is atherosclerosis and its primary complication – acute heart attack brought on by its molecular mechanisms – and the innovative possibilities of interventional therapy. Albert Schömig was able to develop new therapeutic concepts and catheter technology out of basic research and to test them in extensive clinical studies. In 1992, he accepted a professorship in internal medicine at TUM and became the director of the first medical clinic at the university hospital Klinikum rechts der Isar. Additionally, he took over the Cardiovascular Disease Clinic at the German Heart Center Munich. Under his direction, cardiology and angiology at TUM developed into one of the greatest cardiovascular centers of excellence in Europe. In addition, he started the Isar-Zentrum in Munich, the largest academic research organization for interventional cardiology in Germany. From 2005 to 2012, Albert Schömig served two terms as medical director of the German Heart Center Munich and was instrumental in restructuring and expanding its services. His groundbreaking research has justifiably made him one of the leaders of modern interventional cardiology. In a ranking of the 50 most cited German-speaking heart researchers from 2004 to 2007, carried out by Laborjournal magazine, Albert Schömig topped the list and, according to the h-index of ISI statistics, is one of the four most cited scientists and academics at TUM.
|1965 / 1969||Study of medicine at the universities of Würzburg and Heidelberg|
|1972||Doctorate, University of Heidelberg|
|1973-1975||Assistant, Pharmacological Institute, University of Heidelberg|
|1975 - 1983||Intern at the Heidelberg University Hospital|
|1984 - 1987||Chief physician, Medizinische Poliklinik Heidelberg, thereafter at the Heidelberg University Hospital|
|1987 – 1992||University professor and deputy medical director, University of Heidelberg|
|1992 – 2012||Professor of internal medicine and director of the I. Medizinische Klinik und Poliklinik, TUM|
|1995 - 2012||Head of the Department of Cardiology of the German Heart Center Munich|
|2005 - 2007||Medical director, German Heart Center Munich|
|2011 - 2012||Medical director, German Heart Center Munich|
Memberships and honors
Albert Schömig is a member of many national and international professional societies and co-publisher of numerous academic and scientific publications and book contributions
Research residency, Edinburgh, Scotland (1983-1984)
Coordinator of the EU project Cardiogenics (2006-2010)
Head of the ethics commission of the TUM School of Medicine (1995-2012)
Schömig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F, Nekolla SG, Schlotterbeck K, Schühlen H, Pache J, Seyfarth M, Martinoff S, Benzer W, Schmitt C, Dirschinger J, Schwaiger M, Kastrati A: „Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial”. JAMA. 2005; 293:2865-72
Zohlnhöfer D, Ott I, Mehilli J, Schömig K, Michalk F, Ibrahim T, Meisetschlager G, von Wedel J, Bollwein H, Seyfarth M, Dirschinger J, Schmitt C, Schwaiger M, Kastrati A, Schömig A: “Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial”. JAMA. 2006; 295:1003-10.
Schomig A, Dibra A, Windecker S, Mehilli J, Suarez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Juni P, Pfisterer ME, Meier B, Kastrati A: “A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease”. J Am Coll Cardiol. 2007. 50:1373-80.
Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, Khattab AA, Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Schömig A: “Bivalirudin versus unfractionated heparin during percutaneous coronary intervention”. N Engl J Med. 2008; 359:688-96.
Schömig A, Mehilli J, de Waha A, Seyfarth M, Pache J, Kastrati A: “A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease”. J Am Coll Cardiol. 2008; 52: 894-904.